Pathophysiological Characteristics Linking Type 2 Diabetes Mellitus and Colorectal Neoplasia.


Journal

Physiological research
ISSN: 1802-9973
Titre abrégé: Physiol Res
Pays: Czech Republic
ID NLM: 9112413

Informations de publication

Date de publication:
31 08 2021
Historique:
pubmed: 2 6 2021
medline: 28 1 2022
entrez: 1 6 2021
Statut: ppublish

Résumé

A substantial body of literature has provided evidence that type 2 diabetes mellitus (T2DM) and colorectal neoplasia share several common factors. Both diseases are among the leading causes of death worldwide and have an increasing incidence. In addition to usual risk factors such as sedentary lifestyle, obesity, and family history, common pathophysiological mechanisms involved in the development of these diseases have been identified. These include changes in glucose metabolism associated with adipose tissue dysfunction including insulin resistance resulting to hyperinsulinemia and chronic hyperglycemia. In addition to altered glucose metabolism, abdominal obesity has been associated with accented carcinogenesis with chronic subclinical inflammation. An increasing number of studies have recently described the role of the gut microbiota in metabolic diseases including T2DM and the development of colorectal cancer (CRC). Due to the interconnectedness of different pathophysiological processes, it is not entirely clear which factor is crucial in the development of carcinogenesis in patients with T2DM. The aim of this work is to review the current knowledge on the pathophysiological mechanisms of colorectal neoplasia development in individuals with T2DM. Here, we review the potential pathophysiological processes involved in the onset and progression of colorectal neoplasia in patients with T2DM. Uncovering common pathophysiological characteristics is essential for understanding the nature of these diseases and may lead to effective treatment and prevention.

Identifiants

pubmed: 34062073
pii: 934631
doi: 10.33549/physiolres.934631
pmc: PMC8820551

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

509-522

Références

Gastroenterology. 2014 May;146(6):1449-58
pubmed: 24486050
Genome Res. 2012 Feb;22(2):299-306
pubmed: 22009989
J Cancer. 2016 Nov 26;7(15):2346-2359
pubmed: 27994674
Front Endocrinol (Lausanne). 2019 Oct 30;10:703
pubmed: 31736870
FEBS J. 2018 Aug;285(16):2926-2943
pubmed: 29893496
Cancers (Basel). 2019 Sep 19;11(9):
pubmed: 31546918
Immunol Rev. 2017 Sep;279(1):4-7
pubmed: 28856741
Front Oncol. 2020 Sep 29;10:552283
pubmed: 33117687
Metabolism. 2017 Jul;72:120-143
pubmed: 28641779
Biochem Soc Trans. 2016 Oct 15;44(5):1499-1505
pubmed: 27911732
Int J Colorectal Dis. 2020 Aug;35(8):1501-1512
pubmed: 32592092
Int J Cancer. 2017 Jan 15;140(2):292-301
pubmed: 27706816
Contemp Oncol (Pozn). 2019;23(2):63-68
pubmed: 31316286
J Dent Res. 2018 May;97(5):580-588
pubmed: 29439598
Diabetes Care. 2003 May;26(5):1362-8
pubmed: 12716789
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Front Endocrinol (Lausanne). 2018 Mar 12;9:77
pubmed: 29593647
N Engl J Med. 2011 Mar 03;364(9):829-841
pubmed: 21366474
Gut Microbes. 2010 May-Jun;1(3):138-47
pubmed: 20740058
Physiol Res. 2014;63(Suppl 2):S283-91
pubmed: 24908234
Curr Opin Pharmacol. 2017 Dec;37:35-40
pubmed: 28843953
Oncotarget. 2017 Mar 14;8(11):18456-18485
pubmed: 28060743
Eur J Gastroenterol Hepatol. 2001 Apr;13(4):391-6
pubmed: 11338068
Genes Dis. 2017 Feb 14;4(1):25-27
pubmed: 30258905
J Hematol Oncol. 2020 Jun 3;13(1):64
pubmed: 32493414
Target Oncol. 2017 Oct;12(5):571-597
pubmed: 28815409
Obes Rev. 2015 Feb;16(2):127-36
pubmed: 25586506
Diabetes Metab Syndr. 2013 Oct-Dec;7(4):247-50
pubmed: 24290094
Front Immunol. 2016 Jan 05;6:637
pubmed: 26779183
Curr Mol Med. 2013 Jan;13(1):24-57
pubmed: 22834835
Cancers (Basel). 2015 Dec 18;7(4):2466-85
pubmed: 26694467
Gut. 2013 Apr;62(4):561-70
pubmed: 22735569
Endocrinol Metab Clin North Am. 2014 Mar;43(1):167-85
pubmed: 24582097
Nat Rev Cancer. 2015 Aug;15(8):484-98
pubmed: 26205341
Int J Mol Sci. 2018 Nov 16;19(11):
pubmed: 30453495
Diabetol Metab Syndr. 2015 Sep 12;7:75
pubmed: 26366205
Nature. 2010 Mar 4;464(7285):59-65
pubmed: 20203603
Cell. 2017 Jul 27;170(3):411-413
pubmed: 28753421
World J Gastroenterol. 2016 Sep 28;22(36):8103-11
pubmed: 27688652
J BUON. 2015 Jan-Feb;20(1):100-8
pubmed: 25778303
World J Gastroenterol. 2014 May 14;20(18):5177-90
pubmed: 24833848
PLoS One. 2017 Apr 19;12(4):e0176068
pubmed: 28423026
Int J Mol Sci. 2018 Aug 19;19(8):
pubmed: 30126252
Int J Mol Sci. 2019 Oct 03;20(19):
pubmed: 31623387
J Food Drug Anal. 2017 Jan;25(1):111-118
pubmed: 28911528
Front Immunol. 2019 Sep 24;10:2297
pubmed: 31608072
Front Oncol. 2020 Nov 20;10:566430
pubmed: 33330037
BMJ Open. 2016 Jun 27;6(6):e011430
pubmed: 27354075
Lancet Infect Dis. 2015 Oct;15(10):1211-1219
pubmed: 26311042
Compr Physiol. 2018 Dec 13;9(1):1-58
pubmed: 30549014
Am J Cancer Res. 2017 May 01;7(5):1016-1036
pubmed: 28560055
Cancers (Basel). 2020 Feb 05;12(2):
pubmed: 32033443
J Clin Invest. 2019 Oct 1;129(10):4050-4057
pubmed: 31573550
Sci Transl Med. 2015 Jan 21;7(271):271ps1
pubmed: 25609166
Curr Pharm Des. 2018;24(44):5245-5251
pubmed: 30706806
Front Oncol. 2019 Dec 12;9:1399
pubmed: 31921656
World J Gastroenterol. 2011 Jan 28;17(4):444-8
pubmed: 21274373
Appl Microbiol Biotechnol. 2010 Nov;88(5):1077-85
pubmed: 20838789
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
FEBS Lett. 2015 Aug 19;589(18):2388-93
pubmed: 26193421
J Endocrinol. 2014 Feb 10;220(3):361-73
pubmed: 24389593
PeerJ. 2019 Oct 2;7:e7624
pubmed: 31592340
EBioMedicine. 2020 Jan;51:102590
pubmed: 31901868
Physiol Res. 2017 Nov 24;66(5):811-822
pubmed: 28730835
Clin Dev Immunol. 2012;2012:948098
pubmed: 22778768
Front Microbiol. 2015 Oct 06;6:1050
pubmed: 26500616
Neurosci Lett. 2016 Jun 20;625:64-9
pubmed: 27130819
Carcinogenesis. 2018 Apr 5;39(4):515-521
pubmed: 29373651
JAMA. 2012 Feb 1;307(5):491-7
pubmed: 22253363
Biomolecules. 2019 Oct 22;9(10):
pubmed: 31652642
Horm Mol Biol Clin Investig. 2016 Apr 1;26(1):25-42
pubmed: 26910750
Biosci Rep. 2020 Jun 26;40(6):
pubmed: 32452515
World J Gastroenterol. 2015 May 21;21(19):6026-31
pubmed: 26019469
Biomed Pharmacother. 2016 Oct;83:536-541
pubmed: 27447122
Am J Physiol Regul Integr Comp Physiol. 2017 Jun 1;312(6):R938-R947
pubmed: 28356295
Crit Rev Oncol Hematol. 2016 Dec;108:146-153
pubmed: 27931833
Microb Pathog. 2017 Oct;111:362-369
pubmed: 28912092
Clin Microbiol Rev. 2015 Jan;28(1):208-36
pubmed: 25567228
Genome Res. 2012 Feb;22(2):292-8
pubmed: 22009990
J Med Chem. 2017 Sep 14;60(17):7213-7232
pubmed: 28482155
Oncol Rep. 2014 Jun;31(6):2493-8
pubmed: 24700392
Cancer Epidemiol Biomarkers Prev. 2020 Jun;29(6):1107-1119
pubmed: 32179703
Nat Rev Cancer. 2020 Feb;20(2):74-88
pubmed: 31686003
World J Gastroenterol. 2014 Nov 14;20(42):15632-49
pubmed: 25400447
Nat Rev Microbiol. 2013 Aug;11(8):574-85
pubmed: 24020074
Genomics Proteomics Bioinformatics. 2012 Oct;10(5):310-6
pubmed: 23200141
Sci Rep. 2015 Dec 01;5:17591
pubmed: 26620869
Cancer Biol Med. 2016 Mar;13(1):101-19
pubmed: 27144066

Auteurs

T Grega (T)

Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Military University Hospital in Prague, Czech Republic. tomas.grega@uvn.cz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH